Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to -$46.4 million.

  • Corcept Therapeutics' Cash from Financing Activities fell 12005.03% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.7 million, marking a year-over-year decrease of 74153.96%. This contributed to the annual value of -$28.3 million for FY2024, which is 8093.84% up from last year.
  • Corcept Therapeutics' Cash from Financing Activities amounted to -$46.4 million in Q3 2025, which was down 12005.03% from -$102.9 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Cash from Financing Activities high stood at $766000.0 for Q4 2023, and its period low was -$207.0 million during Q4 2021.
  • Its 5-year average for Cash from Financing Activities is -$36.1 million, with a median of -$14.0 million in 2022.
  • In the last 5 years, Corcept Therapeutics' Cash from Financing Activities plummeted by 3121149.77% in 2021 and then skyrocketed by 135573.77% in 2023.
  • Corcept Therapeutics' Cash from Financing Activities (Quarter) stood at -$207.0 million in 2021, then skyrocketed by 99.97% to -$61000.0 in 2022, then skyrocketed by 1355.74% to $766000.0 in 2023, then tumbled by 695.82% to -$4.6 million in 2024, then plummeted by 916.94% to -$46.4 million in 2025.
  • Its last three reported values are -$46.4 million in Q3 2025, -$102.9 million for Q2 2025, and -$39.8 million during Q1 2025.